[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diabetic-foot-ulcers-dfu\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diabetic-foot-ulcers-dfu":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,50,81,111,135],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100639806","nutritional-status-in-adults-with-diabetic-foot-ulcers-100639806",false,"NCT07621770","Nutritional Status in Adults With Diabetic Foot Ulcers","Nutritional Status in Adults With Diabetic Foot in an Outpatient Wound Clinic: A Feasibility and Pilot Study","NutriDFU-P","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosed with diabetes type 1 or type 2\n* Presence of one or more DFUs\n* Receiving treatment in a participating outpatient wound clinic\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Above ankle amputation of the contralateral leg\n* Current treatment with intravenous antibiotics for acute infection.\n* Current hospitalisation for acute surgical management of the foot ulcer\n* Declining or unable to participate in a telephone follow-up interview.\n* Current long-term enteral (tube feeding) or parenteral nutritional support.\n\nExclusion criteria for bioelectrical impedance analysis (BIA)\n\n\\- Presence of a cardiac pacemaker or other implanted electronic device","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","OBSERVATIONAL","This feasibility and pilot study has two aims. The primary aim is to assess the feasibility of collecting clinical, nutritional, and functional data among adults with diabetic foot ulcers (DFUs) who are treated at an outpatient wound clinic. Specifically, the study will evaluate recruitment and inclusion rates, the relevance and clinical utility of selected variables, and assess the completeness and reliability of data collection.\n\nThe secondary aim is to provide a preliminary characterisation of nutritional status, dietary intake, body composition, muscle strength, mobility, and wound-related quality of life, to inform the design and methodology of a future full-scale national study.\n\nDFUs are associated with delayed healing, recurrent infections, reduced quality of life, and increased risk of hospitalization and amputation. These conditions are frequently accompanied by systemic inflammation, impaired circulation, and metabolic disturbances, which may increase nutritional requirements and negatively affect wound healing.\n\nDespite nutrition being recognized as a modifiable factor of ulcer healing, the nutritional status of individuals with DFUs remains insufficiently characterised, and evidence regarding clinically relevant nutritional deficiencies in this population is limited.\n\nParticipants will undergo assessment of height, weight, body composition, handgrip strength, and a 24-hour dietary recall interview during an outpatient clinic visit. Nutritional screening questionnaires and patient-reported measures of appetite, nutritional impact symptoms, mobility, and quality of life will be collected through telephone interviews within one week of the clinical visit.\n\nEligible participants are adults (\\>18 years) who are referred to the outpatient wound clinic with a hard-to-heal foot ulcer. Participants must be able to communicate in Danish or English.",[25,26,27,28,29,30,31],"Diabetic Foot Ulcers (DFU)","Nutrition Assessment","Malnutrition (Calorie)","Ulcer Foot","Dietary Intake Assessment","Bio-Impedance Measurements","Wound Healing",[33,34,35,36,37,38],"DFU","Malnutrition","Wound healing","Nutritional assessment","outpatient","hard-to-heal ulcer","NOT_YET_RECRUITING","2026-05-29",{"date":42,"type":43},"2026-06-02","ACTUAL",{"date":42,"type":21},{"date":46,"type":21},"2026-10-30",{"name":48,"class":49},"Hvidovre University Hospital","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100608169","efficacy-and-safety-of-cold-atmospheric-plasma-combined-with-endovascular-intervention-for-diabetic-foot-ulcers-with-lower-extremity-arterial-occlusion-100608169","NCT07198061","Efficacy and Safety of Cold Atmospheric Plasma Combined With Endovascular Intervention for Diabetic Foot Ulcers With Lower Extremity Arterial Occlusion","Efficacy and Safety of Cold Atmospheric Plasma Combined With Endovascular Intervention for Diabetic Foot Ulcers With Lower Extremity Arterial Occlusion: A Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n* 1)Age between 18 and 80 years; diagnosed with type 1 or type 2 diabetes mellitus; with HbA1c ≤10%;\n* 2)Presence of at least one chronic foot ulcer persisting for ≥3 weeks, with no signs of healing despite guideline-directed standard care; ulcer classified as Wagner-Armstrong grade 1D or 2D;\n* 3)Imaging-confirmed infrapopliteal arterial stenosis or occlusion, assessed by vascular ultrasound and\u002For computed tomography angiography (CTA); all patients must have undergone infrapopliteal balloon angioplasty, with successful target vessel revascularisation confirmed intraoperatively (≤30% residual stenosis);\n* 4)Signed written informed consent prior to study participation.\n\nExclusion Criteria:\n\n* 1)Concurrent use of negative pressure wound therapy (NPWT) or maggot debridement therapy;\n* 2)Undergoing dialysis for end-stage renal disease;\n* 3)Use of topical antibiotics with known biological activity on the wound;\n* 4)Use of platelet-rich fibrin (PRF) for wound treatment;\n* 5)Women of childbearing potential without effective contraception, or currently breastfeeding;\n* 6)Presence of severe comorbidities involving other organ systems, with an estimated life expectancy of less than 6 months;\n* 7)Participation in another clinical trial within the past 3 months, or currently enrolled in another clinical study;\n* 8)Any condition deemed unsuitable for trial participation at the discretion of the investigators.","80 Years",{"count":59,"type":21},40,"INTERVENTIONAL",[62],"NA","The goal of this clinical trial is to evaluate whether cold atmospheric plasma (CAP) combined with endovascular intervention can accelerate wound healing and improve safety outcomes in patients aged 18 to 80 years with diabetic foot ulcers (DFUs) complicated by lower extremity arterial occlusion.\n\nThe main questions it aims to answer are:\n\n1. Does CAP treatment lead to a greater reduction in ulcer area by Week 4 compared to placebo?;\n2. Is CAP therapy safe and well-tolerated in patients with DFUs after successful infrapopliteal revascularisation?;\n\nResearchers will compare CAP treatment plus standard care to sham CAP (placebo) plus standard care to see if CAP improves wound healing more effectively and reduces adverse local symptoms.\n\nParticipants will:\n\n1. Receive either active CAP therapy or sham CAP therapy once daily for 10 days following endovascular revascularisation\n2. Undergo daily wound assessments for ulcer area, signs of infection, and pain scores\n3. Complete quality-of-life questionnaires (EQ-5D and SF-12) at baseline and Week 4\n4. Be followed through Week 4 to assess efficacy and safety endpoints",[25,65],"Lower Extremity Arterial Occlusion",[67,68,69],"Cold Atmospheric Plasma","Diabetic Foot Ulcers","lower extremity arterial occlusion","RECRUITING","2026-04-21",{"date":73,"type":43},"2026-04-22",{"date":75,"type":43},"2025-10-09",{"date":77,"type":21},"2026-12-30",{"name":79,"class":49},"Shenyang Medical College",1,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":91,"conditions":92,"keywords":96,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":80},"100620653","evaluating-the-durability-of-closure-for-diabetic-foot-ulcers-following-a-randomized-controlled-modified-platform-trial-100620653","NCT07360418","Evaluating the Durability of Closure for Diabetic Foot Ulcers Following a Randomized, Controlled, Modified Platform Trial.","A Prospective Multicenter Study Evaluating the Durability of Closure for Diabetic Foot Ulcers Following a Randomized, Controlled, Modified Platform Trial","SCANX","Inclusion Criteria:\n\n* The potential subject must have participated in the CAMPX trial and achieved complete closure by the 12-week endpoint.\n\nExclusion Criteria:\n\n* The potential subject did not participate in the CAMPX trial.\n* The potential subject participated in the CAMPX trial and did not achieve complete closure.",{"count":90,"type":21},50,"Prospective long-term follow-up on durability of closure evaluated by photographic and thermal scanning.",[25,93,94,95],"Foot Ulcer Chronic","Ulcer","Diabetic Foot Ulcer",[97,98,99,100],"CAMPX","CAMP","Foot Ulcer","diabetic foot ulcer","2026-02-09",{"date":103,"type":43},"2026-02-10",{"date":105,"type":43},"2025-10-16",{"date":107,"type":21},"2027-10",{"name":109,"class":110},"Applied Biologics, LLC","INDUSTRY",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":119,"targetDuration":4,"studyType":60,"phases":121,"briefSummary":122,"conditions":123,"keywords":124,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":80},"100598557","efficacy-and-safety-of-cold-atmospheric-plasma-combined-with-endovascular-intervention-in-patients-with-diabetic-foot-ulcers-and-lower-extremity-arterial-occlusion-100598557","NCT07073040","Efficacy and Safety of Cold Atmospheric Plasma Combined With Endovascular Intervention in Patients With Diabetic Foot Ulcers and Lower Extremity Arterial Occlusion","Efficacy and Safety of Cold Atmospheric Plasma Combined With Endovascular Intervention in Patients With Diabetic Foot Ulcers and Lower Extremity Arterial Occlusion: a Randomized, Double-blind, Placebo-controlled Clinical Trial","PROSPECT","Inclusion Criteria:\n\n* Aged 18-80 years, with a diagnosis of type 1 or type 2 diabetes and diabetic foot ulcer; glycated hemoglobin (HbA1c) ≤ 10%.\n* Presence of at least one chronic foot ulcer persisting for at least three weeks, with no signs of healing after standard-of-care treatment based on current clinical guidelines. The ulcer must be classified as Wagner-Armstrong grade 1D or 2D (Wagner: superficial ulcer \\[grade 1\\] or ulcer extending to tendon \\[grade 2\\]; Armstrong: presence of both ischaemia and infection \\[stage D\\]).\n* Documented infrapopliteal arterial stenosis or occlusion by vascular ultrasound and\u002For CT angiography (CTA), meeting indications for revascularization. All enrolled patients must have received successful infrapopliteal balloon angioplasty, with intraoperative angiography confirming target artery patency.\n* Provision of written informed consent.\n\nExclusion Criteria:\n\n* Concurrent treatment of the wound with local vacuum therapy or maggot therapy.\n* Undergoing dialysis.\n* Use of local active antibiotics.\n* Treatment with platelet-rich fibrin.\n* Women of childbearing potential without effective contraception, or women who are actively breastfeeding.\n* Presence of other severe organ dysfunction, with an expected survival of less than six months.\n* Participation in another clinical trial within the past three months or currently enrolled in another clinical trial.",{"count":120,"type":21},86,[62],"Critical limb ischemia is the end-stage manifestation of peripheral arterial disease (PAD), frequently presenting as ischemic rest pain, ulceration, or gangrene. Diabetes mellitus is a major risk factor for lower extremity arterial occlusion, with infrapopliteal arteries most commonly affected. Patients with diabetic foot ulcers (DFUs) have a high prevalence of neurovascular complications, poor healing, and elevated amputation and mortality rates. Large-scale cohort studies indicate that five-year survival after amputation in this population is only about 50%, underscoring the need for more effective therapies.\n\nEndovascular revascularization has become the first-line treatment for diabetic lower limb ischemia. However, despite successful revascularization, persistent microvascular dysfunction and difficult-to-heal ulcers remain common due to chronic inflammation, impaired angiogenesis, and tissue repair deficits. Current advanced wound dressings provide limited benefit and are often costly.\n\nCold atmospheric plasma (CAP) has emerged as a promising adjunctive therapy, with demonstrated antimicrobial activity-including efficacy against multidrug-resistant organisms-and the ability to promote microcirculation and wound healing. CAP generates reactive oxygen and nitrogen species that disrupt bacterial membranes and may also stimulate tissue regeneration. Preclinical and clinical studies suggest that CAP can accelerate healing in chronic wounds and is well tolerated by patients.\n\nGiven these advantages, the present study aims to assess the efficacy and safety of CAP combined with endovascular intervention in patients with diabetic foot ulcers and lower extremity arterial occlusion, to inform future clinical application of this novel technology.",[25,65],[125,126,69],"cold atmospheric plasma","diabetic foot ulcers","2026-01-29",{"date":129,"type":43},"2026-01-30",{"date":131,"type":43},"2025-07-22",{"date":133,"type":21},"2026-05-06",{"name":79,"class":49},{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":4},"100573522","evaluation-of-left-ventricular-function-after-treatment-of-diabetic-foot-ulcers-using-longitudinal-strain-echocardiography-100573522","NCT06747377","Evaluation of Left Ventricular Function After Treatment of Diabetic Foot Ulcers Using Longitudinal Strain Echocardiography","Inclusion Criteria:\n\n* Diabetic Patients with DFU, who were diagnosed by a vascular surgeon based on Diabetic Foot Study Group guidelines.\n* Diabetic Patients were who used anti-diabetic oral medication, insulin or who had fasting blood glucose (FBS) ≥ 126 mg\u002Fdl for at least two times at age group 18 to 50 years at Assiut university hospital\n\nExclusion Criteria:\n\n* Patients with acute or advanced stage of renal, hepatic or pulmonary diseases, acute coronary syndrome, known coronary artery disease ,infectious disease in the last two weeks, coagulopathy, history of a hemorrhagic stroke, severe valvular disease , heart failure (EF\\\u003C45%).\n* at age group below 18 or above 50 years old.",{"count":142,"type":21},52,"Early detection of heart failure as a macrovascular complication of DM offers the best chance of cure in these patients. Nowadays, the most common method for detecting heart failure is measuring left ventricle ejection fraction (LV-EF), by echocardiography. Despite the easy application of LV-EF, it remains normal in early stages of cardiac disease and it's considered as heart failure with preserved LVEF (HFpEF). We hope that, Strain monitoring as a new method enables us to detect the early minimal changes in myocardium.\n\nThe aim of study evaluate the effect of treatment of diabetic foot ulcers in improving heart function by strain echocardiography than conventional transthoracic echocardiography in Assiut university hospital.",[25],"2024-12-20",{"date":147,"type":43},"2024-12-24",{"date":149,"type":21},"2025-01-01",{"date":151,"type":21},"2026-03-01",{"name":153,"class":49},"Assiut University"]